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OBJECTIVE: The aim of this study was to evaluate the expression of protein tyrosine kinase 2 and protein
tyrosine phosphatase non-receptor type 11, which respectively encode focal adhesion kinase protein and src
homology 2 domain-containing protein-tyrosine phosphatase 2, in hematopoietic cells from patients with
myelodysplastic syndromes.
METHODS: Protein tyrosine kinase 2 and tyrosine phosphatase non-receptor type 11 expressions were analyzed
by quantitative polymerase chain reaction in bone marrow cells from patients with myelodysplastic syndromes
and healthy donors.
RESULTS: Protein tyrosine kinase 2 and tyrosine phosphatase non-receptor type 11 expressions did not
significantly differ between normal cells and myelodysplastic cells.
CONCLUSIONS: Our data suggest that despite the relevance of focal adhesion kinase and src homology 2 domain-
containing protein-tyrosine phosphatase 2 in hematopoietic disorders, their mRNA expression do not significantly
differ between total bone marrow cells from patients with myelodysplastic syndromes and healthy donors.
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& INTRODUCTION
Myelodysplastic syndromes (MDS) encompass a group of
hematological disorders characterized by impaired hemato-
poiesis and a risk of progression to acute myeloid leukemia
(AML). Low-risk MDS patients present high levels of
intramedullar apoptosis, whereas high-risk MDS patients
have impaired cell differentiation and increased cell
proliferation (1). Aberrant gene expression is involved in
the pathogenesis of MDS and the progression to AML (2).
Therefore, studies on the expression of genes involved in
cell proliferation, survival and differentiation are important
to help elucidate this disease.
Two genes that participate in fundamental cellular
processes are protein tyrosine kinase 2 (PTK2) and protein
tyrosine phosphatase non-receptor type 11 (PTPN11). PTK2
encodes focal adhesion kinase (FAK), a tyrosine kinase
involved in cell proliferation, adhesion and migration (3).
FAK is overexpressed in several cancers and its expression
usually correlates with a poor prognosis (3). Recent
evidences indicate that FAK plays a role in hematopoietic
disorders. FAK is upregulated in AML and enhances the
migration of leukemic cells from the marrow to circulation,
confers drug resistance, and negatively influences the
clinical outcome (4). FAK splice variants are abnormally
expressed in the primary leukemic cells of AML patients
with poor prognosis and induced an increase in the
clonogenicity of normal human hematopoietic progenitor
cells (5). Moreover, the silencing of this protein in erythroid
and myeloid progenitors resulted in a reduced cell growth
and survival in response to cytokines, and in a defective
activation and expression of antiapoptotic proteins (6).
PTPN11 encodes src homology 2 domain-containing
protein-tyrosine phosphatase 2 (SHP2), a tyrosine phospha-
tase with critical cell properties, including the regulation
of proliferation, apoptosis, and differentiation (7). SHP2
expression levels are elevated in AML and are related to the
hyperproliferative capacity and the degree of differentiation of
primary leukemia cells (8). Animal models lacking SHP2
expression in hematopoietic tissues presented peripheral blood
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and bone marrow cytopenia (9,10), in addition to increased
apoptosis and a reduced quiescence and repopulation capacity
of hematopoietic stem cells (10). SHP2 knockdown in normal
human cord blood CD34+ cells strongly inhibited cell survival,
proliferation, and differentiation in response to growth factor
stimuli (11).
Despite the fact that both FAK and SHP2 are upregulated
in AML, there are few studies in MDS. Therefore, we aimed
to evaluate FAK and SHP2 mRNA expression in bone
marrow cells from healthy donors and MDS patients.
& MATERIALS AND METHODS
Bone marrow samples
Bone marrow aspirates were obtained from 43 patients
diagnosed with MDS (median age: 66 years, range: 16-85
years) before treatment, and from 13 healthy donors
(median age: 31 years, range: 18-56 years). This study was
approved by the National Ethical Committee Board.
Patients’ characteristics are described in Table 1. The
patients were grouped into low- and high-risk MDS
according to the World Health Organization (WHO)
(12,13) and French American British (FAB) (14) classifica-
tions, and the International Prognostic Score System (IPSS)
(15).
Quantitative polymerase chain reaction (qPCR)
Bone marrow samples were submitted to RNA extraction
using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
after removal of erythrocytes by hemolysis. The reverse
transcription reaction was performed using the
RevertAidTM First Strand cDNA Synthesis Kit (MBI
Fermentas, St. Leon-Rot, Germany). Gene expression was
evaluated by qPCR in an ABI 7500 Sequence Detector
System (Applied Biosystems, Foster City, CA, USA), using
specific primers for amplification of PTK2 and PTPN11 and
the suitable housekeeping gene HPRT. Primer sequences are
described in Table 2. The relative quantification value of
gene expression was calculated using the equation 2-DDCT
(16).
Statistical analysis
Statistical analyses were performed using GraphPad
Instat 5 (GraphPad Software, Inc., San Diego, CA, USA).
The Mann-Whitney test was used for comparisons between
groups. The level of significance was set at p,0.05.
& RESULTS
We observed no differences in PTK2 expression between
normal and MDS bone marrow cells (median [range]: 1.00
[0.01-3.39] vs. 1.30 [0.01-8.10]; Figure 1A). PTK2 expression
did not differ between low- and high-risk MDS patients
according to WHO classification (1.29 [0.01-8.10] vs. 0.60
[0.04-2.20]), IPSS (1.15 [0.01-4.95] vs. 1.79 [0.55-8.10]), or FAB
classification (1.26 [0.01-4.95] vs. 1.40 [0.04-8.10]) (Figure 1B-
D) and cytogenetic risk (low-risk: 1.09 [0.01-4.95] vs. inter-
mediate/high-risk: 1.40 [0.55-8.10]); all p.0.05. Interestingly,
theMDSpatient who had presented the highest percentage of
bone marrow blasts (23%) also presented the highest levels of
PTK2 (6.2-fold above the median of the MDS group).
Regarding the analysis of PTPN11 gene, we observed a
heterogeneous expression and no significant differences
between normal and MDS bone marrow cells (1.00 [0.11-
17.39] vs. 0.58 [0.01-7.36]; Figure 2A). The comparison
between low- and high-risk MDS patients demonstrated a
non-significant increase in PTPN11 expression in the high-
risk group according to the WHO classification (0.54 [0.04-
7.36] vs. 1.02 [0.05-4.24]), IPSS (0.54 [0.01-7.36] vs. 1.71 [0.10-
2.80]) and FAB classification (0.54 [0.01-17.36] vs. 1.08 [0.05-
4.24]) (Figure 2B-D). In addition, there was no significant
difference in the cytogenetic risk between low- and
intermediate/high-risk patients (low risk: 0.54 [0.01-7.36]
vs. intermediate/high-risk: 2.52 [0.10-2.80]; all p.0.05).
Table 1 - Patient characteristics.
Patient characteristics Number
MDS patients 43
Gender
Male/Female 29/14
Age (years), median (range) 66 (16-85)
WHO
Low-risk group: RCUD/RCMD/RARS 4/20/7
High-risk group: RAEB-1/RAEB-2 6/3
AML with myelodysplasia-related changes* 3
IPSS
Low-risk group: Low-risk/INT-1 17/19
High-risk group: INT-2/High-risk 5/1
Not available 1
FAB
Low-risk group: RA/RARS 24/7
High-risk group: RAEB/RAEBt 8/4
Cytogenetic risk
Low risk 36/1
Intermediate risk 3
High risk 2
Not available 1
Karyotype
Normal karyotype 36
-Y 1
Monosomy 7 2
Trisomy 8 3
Not available 1
Number of cytopenic cell
0/1 5/12
2/3 19/7
BM blast (%)
,5% 31
$5 and ,10% 6
$10 and ,20% 3
$20 and ,30% 3
WHO: World Health Organization; RCUD: Refractory Cytopenia with
Unilineage Dysplasia; RCMD: Refractory Cytopenia with Multilineage
Dysplasia; RAEB-1: Refractory Anemia with Excess Blasts-1; RAEB-2:
Refractory Anemia with Excess Blasts-2; AML: Acute Myeloid Leukemia;
IPSS: International Prognostic Score System; INT-1: Intermediate-1; INT-2:
Intermediate-2; FAB: French American British; RA: Refractory Anemia;
RARS: Refractory Anemia with Ringed Sideroblasts; RAEB: Refractory
Anemia with Excess Blasts; RAEBt: Refractory Anemia with Excess Blasts in
Transformation; BM: bone marrow; *Excluded from the WHO
classification analysis.
Table 2 - Primer sequences and concentrations.
Gene Sequence Concentration
PTK2 FW: 59- GCGTCTAATCCGACAGCAACA -39
RV: 59- CTCGAGAGAGTCTCACATCAGGTT -39
300 nM
PTPN11 FW: 59- CCGCTCATGACTATACGCTAAG -39
RV: 59-AGACCGTTCTCTCCGTATTCC -39
400 nM
HPRT FW: 59- GAACGTCTTGCTCGAGATGTG -39
RV: 59- TCCAGCAGGTCAGCAAAGAAT -39
150 nM
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& DISCUSSION
Several studies have reported that FAK and SHP2 are
involved in hematopoietic disorders (7,17), which reinforces
the need to assess these proteins in MDS. A recent study
showed that the increased expression of heat shock protein
90 (HSP90) in mononuclear and CD34+ cells from MDS
patients was associated with increased FAK expression and
phosphorylation. Moreover, the expression of HSP90, FAK,
and pFAK increased after transformation and was related
with a poor prognosis or adverse cytogenetics (18).
Mesenchymal stromal cells from high-risk MDS patients
also presented increased expression and nuclear co-localiza-
tion of paxillin, pFAK, and HSP90, which correlated with a
proliferative advantage of these cells and negatively
impacted the clonogenicity of progenitor cells (19). In our
study, despite the role of FAK protein expression and
activity in MDS cells, we observed no differences in FAK
mRNA expression between total bone marrow samples from
MDS patients and healthy donors. FAK expression varies
according to the hematopoietic cell lineage, and different FAK
signaling pathways seem to be triggered according to cell type
(3), regulating different aspects of cell behavior, such as
proliferation, survival, motility, and interactions between
progenitor cells and the bone marrow microenvironment (17).
Moreover, FAK phosphorylation is known to play important
roles, activating intracellular signaling pathways downstream
of integrins and growth factors (17). Therefore, we anticipate
that FAKmRNA expression is not abnormal in MDS total bone
marrow cells. Furthermore, studies regarding FAK protein
Figure 1 - PTK2 expression in normal and MDS bone marrow cells. (A) PTK2 mRNA expression in total bone marrow cells from healthy
donors and MDS patients evaluated by qPCR. (B) PTK2mRNA expression in low-risk and high-risk MDS patients according to the World
Health Organization (WHO) classification, (C) the International Prognostic Score System (IPSS) and (D) the French American British (FAB)
classification. Horizontal lines represent median values.
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expression and activation in isolated hematopoietic cell lineages
may help to explain the possible role of this protein in MDS.
PTPN11 expression did not differ between normal and
MDS bone marrow cells. We observed an increased PTPN11
expression in high-risk MDS patients compared with low-
risk patients; however, the difference was not significant.
The small number of high-risk MDS patients may have
affected the results; therefore, it is possible that a higher
expression of SHP2 is implicated in some cases of MDS,
reflecting the heterogeneity of the disease.
In addition to gene expression, mutations and phosphoryla-
tion are important SHP2 regulatory events. PTPN11mutations
are associated with hematological disorders. PTPN11
mutations are present in more than 30% of patients with
juvenile myelomonocytic leukemia and result in constitutive
activation of the Ras signaling pathway and other effectors,
deregulating myeloid growth (20). However, PTPN11 muta-
tions do not represent a major molecular event in de novoMDS
(21). Phosphorylation of SHP2 follows growth factor or
cytokine stimulation and leads to the activation of the PI3K/
Akt and RAS/MAPK signaling pathways, which are related to
apoptosis and cell proliferation (3,7). SHP2 was found to be
constitutively phosphorylated in leukemic cells and in normal
hematopoietic cells after mitogenic stimulation, suggesting a
correlation between its expression/activation and the hyper-
proliferative phenotype of leukemia (8). Therefore, as with
Figure 2 - PTPN11 expression in normal and MDS bone marrow cells. (A) PTPN11 mRNA expression in total bone marrow cells from
healthy donors and MDS patients evaluated by qPCR. (B) PTPN11mRNA expression in low-risk and high-risk MDS patients according to
the World Health Organization (WHO) classification, (C) the International Prognostic Score System (IPSS) and (D) the French American
British (FAB) classification. Horizontal lines represent median values.
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FAK, it would be interesting to investigate whether the
activation of SHP2, rather thanmRNA expression, participates
in the pathophysiology of MDS.
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